Roger P. Smith, M.D. is a clinical advisor for PDC providing specific expertise in the development of the company’s primary dysmenorrhea program. Dr. Smith is currently a Professor and Vice Chairman of the Department of Obstetrics and Gynecology at the University of Missouri-Kansas City, Truman Medical Centre where he is also an attending physician. Dr. Smith has a special interest in primary dysmenorrhea and has been instrumental in the clinical development of compounds such as anti-inflammatory agents for the treatment of this condition.

Dr. Smith is also an expert in the analysis of intrauterine pressure data used to evaluate the effect of agents in the treatment of dysmenorrhea. Dr. Smith is recognized as an expert in the treatment of dysmenorrhea and has given presentations at national, regional and state meetings on this disorder and written numerous peer-reviewed articles and therapeutic area reviews as well as book chapters on the subject. For the past two years Dr. Smith has presented “Cramping Your Style? New options and concepts in dysmenorrhea therapy,” at the Annual Clinical Conference of The American College of Obstetricians and Gynecologists.

David Olson, PhD acts a scientific advisor for the company's preclinical and clinical programs. He is Director, Perinatal Research Centre and Professor, Depts. Obstetrics & Gynaecology, Physiology and Pediatrics at the University of Alberta. His research focus is exploring the role of prostaglandins in the control of birth in women. Dr. Olson’s laboratory also studies the various genetic, physiological and environmental factors that contribute to both term and preterm labour. His long-term objective is to translate basic science discoveries to practical therapeutic applications to improve the health of mothers and babies. Dr. Olson has conducted and published studies on two of the company's peptides in animal models of preterm birth.

Head of the Preterm Labour department at the AKH in Vienna

Professor Helmer graduated from the University of Vienna in 1987. Following a Fellowship with Anna-Riitta Fuchs at Cornell University Medical College, New York, he completed his residency at the University of Vienna, General Hospital. Professor Helmer has been a Senior Physician in the Department of Obstetrics and Gynaecology at the University of Vienna since 1999. He is an experienced clinical researcher in preterm labour and has published numerous scientific papers and presented his findings at international congresses on his research in preterm labour including clinical studies with atosiban.

Susan Wray is a Professor in the Physiology Department at the University of Liverpool. Prof. Wray's main research goal has been to elucidate the relationship between metabolism and function in uterine smooth muscle and thereby to gain an insight into normal and abnormal functioning of this tissue. Her work is supported by numerous research grants including the MRC, Action Medical Research and WellBeing of Women, Wellcome Trust, BHF and Mersey Kidney Research.

Prof. Wray is an internationally recognized research and each year she is an invited speaker at variety of seminars, lectures or meetings in North America, Europe and Japan, the most recent of which include The Physiological Society, Neonatal Society, European Smooth Muscle Society, IUPS and the Society of Gynecologic Investigation, as well as several universities in Europe and the United States. She is also a trained mentor for newly appointed staff in Liverpool and was on the panel of North West Universities Mentoring Scheme and has been Director of Graduate Studies for the School of Biomedical Science (Anatomy, Physiology and Pharmacology), member of Faculty Higher Degrees Committee and a member of The Irish Health Research Board's Postgraduate Training Review Panel.

Prof. Wray was elected a Fellow of the Academy of Medical Sciences in 2002, FRCOG ad eundem 2006 and Academia Europaea in 2008. Previously, she worked in the Physiology Department at University College London where she gained her BSc and her PhD. She was a member of the Physiological Society Committee, Editor and then Secretary to the Board of the Journal of Physiology and Editor of News in Physiological Sciences and is currently Editor of Experimental Physiology and advisor to Norwegian Research Council.

Dr. Chemtob is Professor of Pediatrics, Ophthalmology, Optometry and Pharmacology, Université de Montréal and Adjunct Professor of Pharmacology, McGill University. He is also a neonatologist (MD: U Montreal; residency & fellowship: McGill U) and pharmacologist (PhD: McGill) and professor of Pediatrics, Ophthalmology, Optometry and Pharmacology at Université de Montréal, Canada. Dr. Chemtob holds a Research Chair (perinatology), the Leopoldine Wolfe Chair in translational vision research, and is author of over 200 articles reported in major journals. He is a scientific founder of two biotechnology companies (Pharma-G, Allostera Pharma), based on his discovery research in the area of novel allosteric inhibitors of G-protein coupled receptors. Dr. Chemtob's research has been supported by major national Canadian (MRC/CIHR, FRSQ, VRQ, MDEIE) and foreign (US [NIH]) grants as well as foundations (eg. AHA, HSFC, MOD). He has been a recipient of numerous awards and is a member of the Canadian Academy of Health Sciences, and appointed as adjunct professor at Université Paris Descartes. He has been member of various scientific committees at the CIHR (CI-A, Fellowship, strategic initiatives, etc), the NIH, CFI, FRSQ, and was on the Advisory Board of IHDCYH of the CIHR. He is co-director of the Vision Network of Quebec, and also serves in a consulting role to three other major Canadian biotechnology companies.